search button

Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification

  • Authors:
    • Ghada Al‑Kafaji
    • Harun Muayad Said
    • Mahmood Abduljalil Alam
    • Ziad Tarraq Al Naieb

  • View Affiliations

  • Published online on: May 22, 2018     https://doi.org/10.3892/ol.2018.8778
  • Pages: 1357-1365
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PCa) is the second most diagnosed malignancy, and the leading cause of cancer‑associated mortality among males. Prostate‑specific antigen (PSA) has long been used for the detection of PCa. However, PSA levels increase in PCa and benign prostatic hyperplasia (BPH), and are associated with a poor disease outcome. Circulating microRNAs (miRNAs) have been determined to be highly stable in the circulation, and could be utilized as biomarkers to improve disease diagnosis and management. In the present study, the effectiveness of four PCa‑associated miRNAs in the discrimination of PCa from BPH and the risk‑stratification of PCa was assessed. The study included 100 participants: 35 patients with localized PCa, 35 patients with BPH and 30 healthy subjects. Patients with PCa were categorized based on their tumor stage (T), PSA level and Gleason score (GS) into low‑(T 1/2, PSA <10 ng/ml or GS ≤7) and high‑risk groups (T 3/4, PSA >20 ng/ml or GS ≥8). Reverse transcription‑quantitative polymerase chain reaction was employed to assess the miRNA expression in peripheral blood samples. Significantly reduced expression of miR‑15a, miR‑126, miR‑192 and miR‑377 was observed in patients with PCa compared with patients with BPH and healthy subjects. In addition, the expression of the four miRNAs was lower in high‑risk PCa patients than in low‑risk PCa patients, with miR‑126 being the most downregulated. The expression of the four miRNAs was also significantly and independently associated with PCa. Receiver operating characteristic curve analysis revealed a significant ability of the miRNAs to distinguish patients with PCa from those with BPH, patients with PCa from controls and low‑risk PCa from high‑risk PCa. These data suggested that expression of these miRNAs in the blood circulation may be promising, non‑invasive biomarkers for the early detection of localized PCa, and for PCa risk stratification. Further validations of the clinical implementation of these results are warranted in a larger cohort.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Al‑Kafaji G, Said HM, Alam MA and Al Naieb ZT: Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification. Oncol Lett 16: 1357-1365, 2018
APA
Al‑Kafaji, G., Said, H.M., Alam, M.A., & Al Naieb, Z.T. (2018). Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification. Oncology Letters, 16, 1357-1365. https://doi.org/10.3892/ol.2018.8778
MLA
Al‑Kafaji, G., Said, H. M., Alam, M. A., Al Naieb, Z. T."Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification". Oncology Letters 16.1 (2018): 1357-1365.
Chicago
Al‑Kafaji, G., Said, H. M., Alam, M. A., Al Naieb, Z. T."Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification". Oncology Letters 16, no. 1 (2018): 1357-1365. https://doi.org/10.3892/ol.2018.8778